Literature DB >> 18639420

Usefulness of the Hardman index in predicting outcome after endovascular repair of ruptured abdominal aortic aneurysms.

Christos D Karkos1, Dimitrios Karamanos, Konstantinos O Papazoglou, Alexandros S Kantas, Evangelia G Theochari, Apostolos G Kamparoudis, Thomas S Gerassimidis.   

Abstract

OBJECTIVES: The Hardman index, which has five variables, has been recommended as a predictor of outcome after open repair of ruptured abdominal aortic aneurysms (RAAAs). It has been reported that the presence of three or more variables is uniformly fatal. The aim of this study was to test the same model in an independent series of RAAA patients undergoing endovascular repair.
METHODS: A consecutive series of 41 patients undergoing endovascular repair for RAAA during an 8-year period was analyzed retrospectively. Thirty-day mortality and patient variables, including the five Hardman risk factors of age >76 years, serum creatinine >190 micromol/L, hemoglobin <9 g/dL, loss of consciousness, and electrocardiographic (ECG) evidence of ischemia, were recorded. The Hardman index and a revised version of the index with four variables (without ECG ischemia) were calculated and related to clinical outcome.
RESULTS: Operative mortality was 41% (17 of 41). On univariate analysis, only age >76 years (P = .01) and the use of local anesthesia (P < .0001) were statistically significant. Loss of consciousness (P = .05) showed a trend toward a higher mortality, albeit not statistically significant. On multivariate analysis, the use of local anesthesia was the only significant predictor of survival (odds ratio [OR], 0.03; 95% confidence interval [CI], 0.003-0.25, P = .001). Again, loss of consciousness showed an association with a higher chance of dying but did not achieve statistical significance (OR, 6.30; 95% CI, 0.93-42.51, P = .059). The original and revised versions of the Hardman index were both significantly associated with death (P = .02 and P = .001, chi(2) test for trend). The cumulative effect of 0, 1, 2, and >/=3 risk factors on mortality was 0%, 27%, 36%, and 71% for the original index, and 12.5%, 21%, 60%, and 78% for the revised version, respectively. Four and two patients with a score of >/=3 in each version of the index survived endovascular repair.
CONCLUSIONS: The Hardman index, with or without incorporating ECG ischemia, seems to be a simple and useful predictive tool in patients undergoing endovascular repair of RAAA, with the mortality rate increasing along with the Hardman score. However, the index cannot be used to accurately identify patients with no chance of survival after endovascular repair.

Entities:  

Mesh:

Year:  2008        PMID: 18639420     DOI: 10.1016/j.jvs.2008.05.065

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  4 in total

1.  Open surgery (OS) versus endovascular aneurysm repair (EVAR) for hemodynamically stable and unstable ruptured abdominal aortic aneurysm (rAAA).

Authors:  Simeng Zhang; Jiaxuan Feng; Haiyan Li; Yongxue Zhang; Qingsheng Lu; Zaiping Jing
Journal:  Heart Vessels       Date:  2015-09-03       Impact factor: 2.037

2.  Comparative effectiveness of open surgery versus endovascular repair for hemodynamically stable and unstable ruptured abdominal aortic aneurysm.

Authors:  Tiehao Wang; Jichun Zhao; Ding Yuan; Yukui Ma; Bin Huang; Yi Yang; Guojun Zeng
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

Review 3.  A systematic review and meta-analysis of the use of resuscitative endovascular balloon occlusion of the aorta in the management of major exsanguination.

Authors:  B L S Borger van der Burg; Thijs T C F van Dongen; J J Morrison; P P A Hedeman Joosten; J J DuBose; T M Hörer; R Hoencamp
Journal:  Eur J Trauma Emerg Surg       Date:  2018-05-21       Impact factor: 3.693

Review 4.  Endovascular vs. Open Repair for Ruptured Abdominal Aortic Aneurysm.

Authors:  Nikolaos Patelis; Demetrios Moris; Georgios Karaolanis; Sotiris Georgopoulos
Journal:  Med Sci Monit Basic Res       Date:  2016-04-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.